J&J: diabetes drug Invokana reduces cardiovascular risks.
(CercleFinance.com) - Johnson & Johnson's Invokana significantly reduced the combined risk of cardiovascular death, myocardial infarction and stroke in a programme assessing the drug's efficacy and safety in diabetes patients.
Study results published in the New England Journal of Medicine showed the product significantly reduced those risks versus placebo in patients with type-2 diabetes mellitus (T2DM) at risk for—or with a history of—cardiovascular disease.
The data were presented in a special symposium at the American Diabetes Association's scientific sessions yesterday in San Diego.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Study results published in the New England Journal of Medicine showed the product significantly reduced those risks versus placebo in patients with type-2 diabetes mellitus (T2DM) at risk for—or with a history of—cardiovascular disease.
The data were presented in a special symposium at the American Diabetes Association's scientific sessions yesterday in San Diego.
Copyright (c) 2017 CercleFinance.com. All rights reserved.